Crisaborole and its potential role in treating atopic dermatitis: Overview of early clinical studies

Immunotherapy

Volumn 8, Issue 8, 2016, Pages 853-866

  Zane, L T ^a   Chanda, S ^a   Jarnagin, K ^a   Nelson, D B ^a   Spelman, L ^b   Gold, L F Stein ^c  

^a PFIZER INC   (United States)

^b Veracity Clinical Research   (Australia)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Atopic dermatitis; Crisaborole Topical Ointment, 2 ; cytokine; inflammation; pharmacokinetics; phosphodiesterase 4 inhibitor; pruritus; quality of life; topical calcineurin inhibitor; Topical corticosteroid

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CRISABOROLE; PHOSPHODIESTERASE IV; PIMECROLIMUS; PROBIOTIC AGENT; TACROLIMUS; VITAMIN D; BORON DERIVATIVE; FUSED HETEROCYCLIC RINGS; NONSTEROID ANTIINFLAMMATORY AGENT; OINTMENT; PHOSPHODIESTERASE IV INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE DERMATITIS; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ATOPIC DERMATITIS; DIET THERAPY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENE MUTATION; HUMAN; INFLAMMATION; MAXIMUM PLASMA CONCENTRATION; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SECONDARY INFECTION; SKIN ATROPHY; SKIN BURNING SENSATION; SYSTEMIC DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; ADULT; ANIMAL; CHILD; CLINICAL TRIAL (TOPIC); DERMATITIS, ATOPIC; OINTMENT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BORON COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CHILD; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; HUMANS; OINTMENTS; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 84979020934     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0023     Document Type: Review

References (89)

1. Bieber T. Atopic dermatitis. N. Engl. J. Med. 358(14), 1483-1494 (2008).
2. Bieber T. Atopic dermatitis. Ann. Dermatol. 22(2), 125-137 (2010).
3. Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr. Allergy Asthma Rep. 8(4), 306-311 (2008).
4. Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis. section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 71(1), 116-132 (2014).
5. Nutten S. Atopic dermatitis. global epidemiology and risk factors. Ann. Nutr. Metab. 66(Suppl. 1), 8-16 (2015).
6. Thomsen SF. Atopic dermatitis. natural history, diagnosis, and treatment. ISRN Allergy 2014, 354250 (2014).
7. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults. European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J. Allergy Clin. Immunol. 118(1), 152-169 (2006).
8. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 150(6), 593-600 (2014).
9. Blume-Peytavi U, Metz M. Atopic dermatitis in children. Management of pruritus. J. Eur. Acad. Dermatol. Venereol. 26(Suppl. 6), 2-8 (2012).
10. Brown MM, Chamlin SL, Smidt AC. Quality of life in pediatric dermatology. Dermatol. Clin. 31(2), 211-221 (2013).
11. Weidinger S, Novak N. Atopic dermatitis. Lancet 387(10023), 1109-1122 (2015).
12. Hanifin JM, Chan SC, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. 107(1), 51-56 (1996).
13. Fowler JF, Duh MS, Rovba L et al. The direct and indirect cost burden of atopic dermatitis. An employer-payer perspective. Manag. Care Interface 20(10), 26-32 (2007).
14. Carr WW. Topical calcineurin inhibitors for atopic dermatitis. Review and treatment recommendations. Paediatr. Drugs 15(4), 303-310 (2013).
15. Romeo SP. Atopic dermatitis. The itch that rashes. Pediatr. Nurs. 21(2), 157-163 (1995).
16. Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of itch in atopic dermatitis. Semin. Cutan. Med. Surg. 30(2), 71-86 (2011).
17. Segal AO, Ellis AK, Kim HL. CSACI position statement. safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin. Immunol. 9(1), 24 (2013).
18. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis. A disease caused by innate immune defects? J. Invest. Dermatol. 129(1), 14-30 (2009).
19. Arkwright PD, Motala C, Subramanian H, Spergel J, Schneider LC, Wollenberg A. Management of difficult-to-treat atopic dermatitis. J. Allergy Clin. Immunol. Pract. 1(2), 142-151 (2013).
20. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin. Dermatol. 21(3), 193-200 (2003).
21. Weber M, Mazzotti N, Petry V, Cestari T, Weis L. Evaluating the relation between pruritus, serum IgE levels and severity of clinical manifestations in atopic dermatitis patients. An. Bras. Dermatol. 80(3), 245-248 (2015).
22. Eyerich K, Novak N. Immunology of atopic eczema. Overcoming the Th1/Th2 paradigm. Allergy 68(8), 974-982 (2013).
23. Barnes KC. An update on the genetics of atopic dermatitis. Scratching the surface in 2009. J. Allergy Clin. Immunol. 125(1), 16-29 (2010).
24. Boguniewicz M, Leung DY. Atopic dermatitis. A disease of altered skin barrier and immune dysregulation. Immunol. Rev. 242(1), 233-246 (2011).
25. Leung DY. New insights into atopic dermatitis. Role of skin barrier and immune dysregulation. Allergol. Int. 62(2), 151-161 (2013).
26. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-part I. Clinical and pathologic concepts. J. Allergy Clin. Immunol. 127(5), 1110-1118 (2011).
27. Bunikowski R, Mielke M, Skarabis H et al. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J. Allergy Clin. Immunol. 103(1 Pt 1), 119-124 (1999).
28. Salt BH, Boguniewicz M, Leung DY. Severe refractory atopic dermatitis in adults is highly atopic. J. Allergy Clin. Immunol. 119(2), 508-509 (2007).
29. Gupta J, Grube E, Ericksen MB et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J. Allergy Clin. Immunol. 121(3), 725-730 (2008).
30. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease. A possible mechanism for cyclic AMP-agonist hyporesponsiveness. J. Allergy Clin. Immunol. 70(6), 452-457 (1982).
31. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm. Allergy Drug Targets 6(1), 17-26 (2007).
32. Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J. Allergy Clin. Immunol. 112(Suppl. 6), S128-S139 (2003).
33. Essayan DM, Huang SK, Kagey-Sobotka A, Lichtenstein LM. Differential efficacy of lymphocyte-and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 99(1 Pt 1), 28-37 (1997).
34. Essayan DM, Huang SK, Undem BJ, Kagey-Sobotka A, Lichtenstein LM. Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 153(8), 3408-3416 (1994).
35. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr. Opin. Investig. Drugs 8(5), 364-372 (2007).
36. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 299(2), 753-759 (2001).
37. Torphy TJ. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157(2), 351-370 (1998).
38. Giembycz MA. Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends Pharmacol. Sci. 17(9), 331-336 (1996).
39. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59(4), 675-680 (1989).
40. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J. Immunol. 185(11), 6413-6419 (2010).
41. Hou S, Guan H, Ricciardi RP. Phosphorylation of serine 337 of NF-kappaB p50 is critical for DNA binding. J. Biol. Chem. 278(46), 45994-45998 (2003).
42. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J. Pharmacol. Exp. Ther. 315(3), 1188-1195 (2005).
43. Chow CW, Davis RJ. Integration of calcium and cyclic AMP signaling pathways by 14-3-3. Mol. Cell. Biol. 20(2), 702-712 (2000).
44. Stork PJ, Dillon TJ. Multiple roles of Rap1 in hematopoietic cells. Complementary versus antagonistic functions. Blood 106(9), 2952-2961 (2005).
45. Mosenden R, Tasken K. Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell. Signal. 23(6), 1009-1016 (2011).
46. Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br. J. Dermatol. 131(3), 383-396 (1994).
47. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br. J. Dermatol. 131(3), 406-416 (1994).
48. Hachisuka J, Takeuchi S, Kido M, Fukiwake N, Furue M. Severity of disease, rather than xerosis, correlates with pruritus in patients with atopic dermatitis. Int. J. Dermatol. 48(4), 374-378 (2009).
49. National Collaborating Centre for Women's and Children's Health (2007). www.ncc-wch.org.uk/
50. Sheehan-Dare RA, Henderson MJ, Cotterill JA. Anxiety and depression in patients with chronic urticaria and generalized pruritus. Br. J. Dermatol. 123(6), 769-774 (1990).
51. Halvorsen JA, Lien L, Dalgard F, Bjertness E, Stern RS. Suicidal ideation, mental health problems, and social function in adolescents with eczema. A population-based study. J. Invest. Dermatol. 134(7), 1847-1854 (2014).
52. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis. Impact on the patient, family, and society. Pediatr. Dermatol. 22(3), 192-199 (2005).
53. Schut C, Bosbach S, Gieler U, Kupfer J. Personality traits, depression and itch in patients with atopic dermatitis in an experimental setting. A regression analysis. Acta Derm. Venereol. 94(1), 20-25 (2014).
54. Dieris-Hirche J, Gieler U, Kupfer JP, Milch WE. [Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis]. Hautarzt 60(8), 641-646 (2009).
55. Simpson EL. Comorbidity in atopic dermatitis. Curr. Dermatol. Rep. 1(1), 29-38 (2012).
56. Kimata H. Prevalence of suicidal ideation in patients with atopic dermatitis. Suicide Life Threat. Behav. 36(1), 120-124 (2006).
57. Dalgard FJ, Gieler U, Tomas-Aragones L et al. The psychological burden of skin diseases. A cross-sectional multicenter study among dermatological out-patients in 13 European countries. J. Invest. Dermatol. 135(4), 984-991 (2015).
58. Noh HM, Cho JJ, Park YS, Kim JH. The relationship between suicidal behaviors and atopic dermatitis in Korean adolescents. J. Health Psychol. pii: 1359105315572453(2015) (Epub ahead of print).
59. Mina S, Jabeen M, Singh S, Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J. Dermatol. 60(2), 211 (2015).
60. Picardi A, Lega I, Tarolla E. Suicide risk in skin disorders. Clin. Dermatol. 31(1), 47-56 (2013).
61. Lewis-Jones S. Quality of life and childhood atopic dermatitis. The misery of living with childhood eczema. Int. J. Clin. Pract. 60(8), 984-992 (2006).
62. Garcia PL, Ebert U. Frontiers of rapid itch relief. A review of methylprednisolone aceponate. J. Eur. Acad. Dermatol. Venereol. 26(Suppl. 6), 9-13 (2012).
63. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 112(Suppl. 6), S118-S127 (2003).
64. Schneider L, Tilles S, Lio P et al. Atopic dermatitis. A practice parameter update 2012. J Allergy Clin. Immunol. 131(2), 295-299 (2013).
65. Lio PA. Non-pharmacologic therapies for atopic dermatitis. Curr. Allergy Asthma Rep. 13(5), 528-538 (2013).
66. Callen J, Chamlin S, Eichenfield LF et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br. J. Dermatol. 156(2), 203-221 (2007).
67. Rathi SK, D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J. Dermatol. 57(4), 251-259 (2012).
68. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol. 127(4), 808-816 (2007).
69. Nnuroka EN, Daramola OOM, Ike SO. Misuse and abuse of topical steroids. Implications. Expert Rev. Dermatol. 2(1), 31-40 (2007).
70. Kragballe K. Topical corticosteroids. Mechanisms of action. Acta Derm. Venereol. 151, 7-10 (1989).
71. Akers WA. Risks of unoccluded topical steroids in clinical trials. Arch. Dermatol. 116(7), 786-788 (1980).
72. Hajar T, Leshem YA, Hanifin JM et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. J. Am. Acad. Dermatol. 72(3), 541-549 (2015).
73. Smith SD, Hong E, Fearns S, Blaszczynski A, Fischer G. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas. J. Dermatol. 51(3), 168-174 (2010).
74. Arellano FM, Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J. Allergy Clin. Immunol. 123(5), 1111-1116 (2009).
75. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 151(6), 594-599 (2015).
76. Luger T, Boguniewicz M, Carr W et al. Pimecrolimus in atopic dermatitis. Consensus on safety and the need to allow use in infants. Pediatr. Allergy Immunol. 26(4), 306-315 (2015).
77. Compound Summary for CID 44591583. PubChem Open Chemistry Database 906673-24-3 (2015). https://pubchem. ncbi.nlm.nih.gov/compound/906673-24-3
78. Akama T, Baker SJ, Zhang YK et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg. Med. Chem. Lett. 19(8), 2129-2132 (2009).
79. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr. Opin. Investig. Drugs 10(11), 1236-1242 (2009).
80. Freund YR, Akama T, Alley MR et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 586(19), 3410-3414 (2012).
81. Jarnagin K, Chanda S, Coronado D et al Crisaborole topical ointment, 2%. A nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J. Drugs Dermatol. 15(4), 390-396 (2016)
82. Zane LT, Kircik L, Call R et al. AN2728 Topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis. A phase 1b, open-label, maximal-use systemic exposure (MUSE) study. Pediatr. Dermatol. (2016). (In Press)
83. Murrell D, Gebauer K, Spelman L, Zane LT. Crisaborole topical ointment, 2% in adults with atopic dermatitis. A Phase 2A, vehicle-controlled, proof-of-concept study. J. Drugs Dermatol. 14(10), 19-23 (2015).
84. Tom WL, Van SM, Chanda S, Zane LT. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis. An open-label Phase 2a study. Pediatr. Dermatol. 33(2), 150-159 (2016).
85. Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J. Drugs Dermatol. 14(12), 1394-1399 (2015).
86. Liu L, Musick TJ, Luo G et al. In vitro and in vivo investigation on metabolic fate of AN2728, a novel boron based small molecules for treatment of psoriasis and atopic dermatitis. Presented at: 18th North American Regional ISSX. Dallas, TX, USA, 14-18 October 2012.
87. Draelos ZD, Stein Gold LF, Murrell DF, Hughes MH, Zane LT. Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis. associated pruritus from Phase 1 and 2 clinical studies. J. Drugs Dermatol. 15(2), 172-176 (2016).
88. Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol. Online J. 20(5), 22608 (2014).
89. Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol. Ther. (Heidelb.) 3(1), 1-15 (2013).